Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Fresenius Kabi Further Expands Oncology Portfolio
Healthcare group Fresenius tops Q4 operating profit forecast
Fresenius Launches Posaconazole Injection for Treatment of Fungal Infections
Fresenius Kabi and Mayo Clinic Enter into Agreement for Ivenix® Infusion System
Fresenius Kabi`s Biologic Idacio (adalimumab) Receives Approval in the U.S.
Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes
Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology
Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient
Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange